Optimized Genomic Literature Mining for Variant Interpretation and Gene Panel Design
Evidence-based method used for selecting content for gene panels
About This EventIn this webinar, a panel of scientific experts will discuss how they used an optimized system for mining the genomic literature for two key applications: variant analysis and the development of evidence-based diagnostic gene panels.
Victor Weigman, Director, Translational Genomics, Q2 Solutions, will present his team's method for selecting the content for gene panels by mining millions of full-text genomic articles to identify disease-gene-variant relationships.
Register now to gain insights into the creation of an evidence-based gene panel in under a week with prioritized literature citations for each biomarker.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.
Updated as of September 2018.